Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Polpharma SA
Polpharma Biologics is making strategic moves to become a truly integrated CDMO by bringing its Dutch Bioceros subsidiary under the Polpharma Biologics brand.
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Polpharma Biologics